Heart failure

Congestive Heart Failure (CHF) Epidemiological Forecast Report 2021-2030 with a focus on United States, Germany, France, Italy, Spain, United Kingdom and Japan – ResearchAndMarkets. com


DUBLIN – (COMMERCIAL THREAD) – The report “Congestive heart failure (CHF) – Epidemiological forecasts – 2030” has been added to ResearchAndMarkets.com offer.

This report “Congestive Heart Failure (CHF) – Epidemiological Forecast-2030” provides an in-depth understanding of HF, historical and predicted epidemiology as well as HF trends in the US, EU5 (Germany , France, Italy, Spain, and the United Kingdom) and Japan.

Epidemiological perspective of congestive heart failure (CHF)

The disease epidemiology covered in the report provides historical and predicted epidemiology segmented by total prevalent population of HF, prevalent population diagnosed with HF, prevalent cases of HF diagnosed by sex, prevalent cases HF diagnosed by age, cases diagnosed by type prevalent cases of HF, prevalent cases of diagnosed HF specific to NYHA class, prevalent cases diagnosed with HF with ejection fraction , diagnosed prevalent cases of HF associated with comorbidities in the 7MM scenario covering the United States, EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2018 to 2030.

Main conclusions

  • The total number of prevalent diagnosed cases of heart failure (HF) in 7MM was 12,602,028 in 2020, which is expected to increase over the study period (2018-2030).

  • Among 7MM, the United States has the highest prevalent population of diagnosed HF, 5,163,119 cases in 2020, representing 40.97% of the total diagnosed cases of HF in 7MM .

  • In the EU-5, Germany has the highest number of diagnosed cases at 2,216,497, followed by Spain with 1,283,827 cases and Italy with 1,164,031 cases. While the UK has the fewest cases with 728,547 in 2020.

  • There are several co-morbidities associated with heart failure, including obesity, hyperlipidemia, metabolic syndrome, and others. Among them in the United States, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871 and 2,065,247 cases were observed in hypertension, diabetes mellitus , chronic kidney disease, atrial fibrillation, COPD, ischemic heart disease and dilated cardiomyopathy.

  • The prevalent cases diagnosed according to age are observed at most in the age group of 75-84 years (1,607,918) and lowest in

  • In 2020, the estimated cases of HFpEF (HFmEF) and HFrEF in the United States were 3,097,871 and 2,065,247, which is expected to increase by 2030.

  • As of 2020, the New York Heart Association (NYHA) classification includes class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation of activity due to symptoms, even during less than usual activity), and class IV cases (severe limitations) which were estimated at 2,633,191, 1,512,794, 516,312 and 516,312 case in the United States.

  • In 2020, the estimated cases of acute heart failure and chronic heart failure in the United States were 1,548,936 and 3,614,183, respectively.

  • Heart failure is a major cause of morbidity and mortality in women, and patients tend to develop it at a later age. According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females in the United States.

Main topics covered:

1. Key information

2. Presentation of the report

3. Executive summary

4. Key events

5. SWOT analysis

6. Congestive Heart Failure (CHF) Market Overview at a Glance

6.1. Market share (%) Breakdown of CHF by therapy in 2021

6.2. Market share (%) Breakdown of CHF by therapy in 2030

7. Background and overview of the disease

7.1. introduction

7.2. Causes of HF

7.3. Signs and symptoms

7.4. Steps of HF

7.5. Classification of HF

7.6. Common pathophysiological mechanisms in HF

7.7. Diagnostic

7.8. Diagnostic tests

7.9. Differential diagnosis

8. Treatment

8.1. Angiotensin converting enzyme (ACE) inhibitors

8.2. Angiotensin II receptor blockers (ARBs)

8.3. Mineralocorticoid receptor antagonists (MRAs)

8.4. Si-Channel Inhibitor

8.5. Beta-blockers

8.6. Angiotensin Receptor Inhibitors (RNAI)

8.7. Diuretics

8.8. Digoxin (Lanoxin)

8.9. Hydralazine and isosorbide dinitrate

8.10. statins

8.11. Anti coagulants

8.12. Dual antiplatelet therapy (DAPT)

8.13. Unique Features of Heart Failure Treatment in Japan

8.14. Non-pharmacological intervention and lifestyle modification

9. Heart failure with preserved ejection fraction: diagnosis and management (2017)

9.1. Main recommendations for practice

9.2. Treatment recommendations

10. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2021)

10.1. Guidelines for diagnosis

10.2. Guidelines for Patients with Heart Failure with Reduced Ejection Fraction (HRrEF)

10.3. Guidelines for heart rhythm management for heart failure with reduced ejection fraction

10.4. Guidelines for Patients with Heart Failure with Slightly Reduced Ejection Fraction (HRmrEF)

10.5. Guidelines for patients with heart failure with preserved ejection fraction (HRpEF)

10.6. Guidelines for the management of multidisciplinary teams for the prevention and treatment of chronic heart failure

10.7. Guidelines for advanced heart failure

10.8. Guidelines for acute heart failure

10.9. Cardiovascular Co-morbidities Guidelines

11. Targeted update of the JCS / JHFS 2021 guidelines on the diagnosis and treatment of acute and chronic heart failure (2017 update)

11.1. Pharmacological treatment guidelines

11.2. Guidelines on If Channel Blocker or HCN Channel Blocker; Ivabradine

11.3. RNAI Guidelines: Sacubitril / valsartan

11.4. SGLT2 Inhibitor Guidelines

11.5. Non-pharmacological treatment guidelines

11.6. Surgical treatment guidelines

11.7. Guidelines for disease management

12. American College of Cardiology (ACC), American Heart Association (AHA) and HF Society of America (HFSA) (2021)

13. Chronic heart failure in adults: diagnosis and management (NICE 2018 guidelines)

13.1. Guidelines for diagnosing heart failure

13.2. Guidelines for the treatment of heart failure with a reduced ejection fraction

13.3. Specialized treatment guidelines

13.4. Guidelines for the treatment of heart failure with reduced ejection fraction in people with chronic kidney disease

13.5. Guidelines for the management of all types of heart failure

13.6. Guidelines on interventional procedures

14. Acute heart failure: diagnosis and management (NICE Guidelines 2014)

14.1. Guidelines for diagnosis, evaluation and follow-up

14.2. Guidelines for initial pharmacological treatment

14.3. Guidelines for initial non-pharmacological treatment

14.4. Guidelines for treatment after stabilization

14.5. Guidelines for Valve Surgery and Percutaneous Intervention

14.6. Guidelines for mechanical assist devices

15. Epidemiology and patient population

15.1. Main conclusions

15.2. Epidemiological methodology

15.3. 7 MM population of patients with heart failure

15.4. Total population of patients with prevalent heart failure diagnosed within 7 MM

16. Country wise-epidemiology of CI

16.1. United States

16.2. UE5

16.3. Japan

17. Organizations contributing to CHF

18. Patient journey

19. Annex

For more information on this report, visit https://www.researchandmarkets.com/r/rp7xfu